Lorlatinib and high cholesterol in ALK+ lung cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Lungs & breathing clinical trials.
This study looks at how the drug Lorlatinib affects cholesterol levels in people with ALK-positive non-small cell lung cancer. It aims to understand and manage these side effects better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced ALK+ non-small cell lung cancer.
- You are between the ages of 18 and 80.
- You are in good enough health to handle daily activities (ECOG score 0-2).
- You have been taking Lorlatinib for at least 20 days.
- You have not been using other anti-cancer drugs during your Lorlatinib treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different ways to manage high cholesterol (hyperlipidemia) that happens as a side effect of the drug lorlatinib, which is used to treat ALK-positive lung cancer. Participants will receive additional cholesterol-lowering medicines or strategies, and the study aims to find the best way to keep cholesterol in check while continuing effective cancer treatment.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This trial tests whether combining a new cholesterol-lowering drug (a PCSK9 inhibitor) with your current lorlatinib can help manage the high cholesterol that lorlatinib may cause, without affecting its anti-cancer effect. It aims to protect your heart health while you continue effective lung cancer treatment.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.